Jefferies Group Comments on MAXIMUS, Inc.’s Q2 2018 Earnings (MMS)

MAXIMUS, Inc. (NYSE:MMS) – Research analysts at Jefferies Group raised their Q2 2018 earnings estimates for shares of MAXIMUS in a note issued to investors on Thursday. Jefferies Group analyst D. Styblo now expects that the health services provider will post earnings per share of $0.83 for the quarter, up from their prior estimate of $0.77. Jefferies Group also issued estimates for MAXIMUS’s Q3 2018 earnings at $0.84 EPS, Q4 2018 earnings at $0.85 EPS and FY2019 earnings at $3.69 EPS.

MAXIMUS (NYSE:MMS) last released its quarterly earnings results on Thursday, November 9th. The health services provider reported $0.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.04. The company had revenue of $620.90 million during the quarter, compared to analyst estimates of $606.86 million. MAXIMUS had a return on equity of 22.93% and a net margin of 8.99%.

Other analysts also recently issued research reports about the stock. Maxim Group reissued a “hold” rating and issued a $69.00 price objective (up previously from $66.00) on shares of MAXIMUS in a research note on Thursday. Canaccord Genuity decreased their price objective on shares of MAXIMUS from $71.00 to $65.00 and set a “hold” rating for the company in a research note on Friday. Finally, Zacks Investment Research raised shares of MAXIMUS from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. One research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company’s stock. MAXIMUS currently has an average rating of “Hold” and an average price target of $67.00.

Shares of MAXIMUS (NYSE MMS) opened at $63.79 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.08. The stock has a market cap of $4,160.58, a PE ratio of 18.99, a price-to-earnings-growth ratio of 2.39 and a beta of 1.21. MAXIMUS has a 12 month low of $55.18 and a 12 month high of $72.71.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 28th. Shareholders of record on Thursday, February 15th will be paid a $0.045 dividend. This represents a $0.18 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Wednesday, February 14th. MAXIMUS’s payout ratio is currently 5.36%.

In other news, Director Russell A. Beliveau sold 1,500 shares of MAXIMUS stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $64.30, for a total transaction of $96,450.00. Following the completion of the sale, the director now owns 40,329 shares of the company’s stock, valued at $2,593,154.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Russell A. Beliveau sold 1,000 shares of MAXIMUS stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $71.73, for a total transaction of $71,730.00. The disclosure for this sale can be found here. In the last three months, insiders sold 67,517 shares of company stock valued at $4,653,302. 3.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of MMS. JPMorgan Chase & Co. raised its stake in shares of MAXIMUS by 459.2% during the second quarter. JPMorgan Chase & Co. now owns 25,842 shares of the health services provider’s stock valued at $1,619,000 after acquiring an additional 21,221 shares in the last quarter. New York State Common Retirement Fund raised its stake in shares of MAXIMUS by 10.0% during the second quarter. New York State Common Retirement Fund now owns 86,332 shares of the health services provider’s stock valued at $5,407,000 after acquiring an additional 7,815 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of MAXIMUS by 1.7% during the second quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the health services provider’s stock valued at $2,186,000 after acquiring an additional 592 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of MAXIMUS by 2.7% during the second quarter. California Public Employees Retirement System now owns 99,900 shares of the health services provider’s stock valued at $6,257,000 after acquiring an additional 2,600 shares in the last quarter. Finally, Voya Investment Management LLC raised its stake in shares of MAXIMUS by 10.9% during the second quarter. Voya Investment Management LLC now owns 29,734 shares of the health services provider’s stock valued at $1,862,000 after acquiring an additional 2,932 shares in the last quarter. 96.44% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/jefferies-group-comments-on-maximus-inc-s-q2-2018-earnings-mms.html.

MAXIMUS Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Earnings History and Estimates for MAXIMUS (NYSE:MMS)

Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply